1.. Introduction
================

Juvenile Idiopathic Arthritis, the most common cause of chronic arthritis in children, encompasses seven clinically heterogeneous categories of arthritis \[[@r1]\]. While the etiology of JIA is unknown, both genetic and environmental factors are believed to influence susceptibility to JIA \[[@r2], [@r3]\]. Relatives of children with JIA have increased prevalence of autoimmunity \[[@r4]\]. Dense genotyping of over 2800 subjects by the international JIA Immunochip Consortium identified 17 variants associated with JIA \[[@r5]\]. However, the entire Immunochip content was estimated to explain only 18% of the risk of JIA, suggesting that other variants also likely play a role in JIA susceptibility.

Functional variants of the gene *PDCD1* which encode the programmed cell death molecule (PD-1), have been associated with systemic lupus erythematosus, rheumatoid arthritis, and progression of multiple sclerosis \[[@r6]-[@r10]\]. A meta-analysis reported association between *PDCD1* variants and RA, ankylosing spondylitis and type 1 diabetes \[[@r11]\]. To our knowledge, *PDCD1* variants have not been previously examined for association with JIA. Given that, clinically distinct autoimmune phenotypes share common genetic susceptibility factors, variants in *PDCD1* were tested for a possible association with JIA.

2.. Subjects and Methods
========================

We genotyped 1689 subjects of Northern European Ancestry, (834 cases and 855 controls). Cases with JIA according to the International League of Associations for Rheumatology criteriaa were enrolled at Pediatric Rheumatology Clinics at the University of Utah and Children's Healthcare of Atlanta under protocols approved by the Institutional Review Boards. Controls were healthy volunteers from Utah who reported no history of autoimmunity at enrollment through the use of a questionnaire as previously reported \[[@r12], [@r13]\].

3.. Genotyping
==============

DNA was isolated from peripheral blood using the Puregene DNA purification kit from Qiagen (Valencia, CA). Subjects were genotyped for four SNPs in the *PDCD1* locus (rs7421861, rs11568821, rs10204525, and rs7568402) using Taqman pre-designed SNP genotyping assays (Applied Biosystems, Foster City, CA) according to the manufacturer's protocols. SNP rs7421861 is located on intron 1, which harbors many splicing control components and regulatory elements \[[@r14]\]. In SNP rs11568821 (also referred to as PD1.3), an A allele disrupts the binding of a Runx1 transcription factor and impairs the inhibitory effect of PD-1. SNP rs10204525 (also referred to as PD 1.6) and rs7568402 are located in the 3' untranslated region, and may affect the inflammatory cytokines levels via modulating polyadenylation.

To ensure quality control, \~9% of the samples were genotyped in duplicate and were found to be concordant. The genotyping success rate was \> 99% of the samples for all 4 SNPs. We have successfully used this method in the past to investigate variants in *TNFA, MIF* and *PTPN22* loci for association with various JIA categories \[[@r15]\].

4.. Statistical Analysis
========================

Prior to association analysis, we tested each variant to confirm that it was in Hardy-Weinberg equilibrium (HWE). We tested each SNP for an additive association with JIA and JIA categories by using logistic regression, adjusting for gender. From the models, we calculated the allelic odds ratios (OR) and 95% confidence intervals (CI). We used permutations to adjust for multiple hypothesis testing. The permutation procedure we implemented allowed us to take into account effects of gender on JIA, as well as preserve linkage disequilibrium patterns of the SNPs. We performed 10,000 permutations under the null hypothesis of no association between genotype and JIA. We performed all analyses using the statistical programming language R. We also attempted to replicate in silico the association observed between *PDCD1* SNP rs7568402 and systemic JIA in a large multi-ethnic systemic JIA case control association study of 982 children with systemic JIA and 8010 healthy controls \[[@r16], [@r17]\]. The final cases and controls used in the meta-analysis were derived after the removal of individuals with ancestral dissimilarities within their strata. Moreover, association testing in each stratum was performed by logistic regression, adjusted for ancestry-informative principal components and gender. This resulted in extremely well matched cases and controls in each geographically defined stratum, as demonstrated by genomic control inflation factors \[[@r16]\]. Some of the systemic JIA cases examined in the present study were also included among the U.S. stratum of the large multi-ethnic systemic association study.

5.. Results
===========

The median age of onset for the cases was 6.6 years and 70% of the subjects were female; 7% of the cases were diagnosed with systemic JIA, 8% with RF positive polyarticular JIA, 26% with RF negative polyarticular JIA, 47% with oligoarticular JIA, 7% with Enthesitis related arthritis (ERA), and 6% with other subtypes. Of the control subjects 60% were female.

All four variants were in HWE in the controls (*p*\>0.10). Using logistic regression, we observed that *PDCD1* variants showed no association with JIA as a combined phenotype (Table **[1](#T1){ref-type="table"}**). However, after stratification two variants were found to be associated with JIA categories (Table **[2](#T2){ref-type="table"}**). *PDCD1* SNP rs11568821 was nominally associated with ERA JIA (OR=0.22, *p*=0.012) in our cohort, but this association was not significant after permutation procedure. Additionally, *PDCD1* SNP rs7568402 was nominally associated with systemic JIA in our cohort (OR=0.53, *p*=0.0027). After the permutation procedure, this association remained significant (*p*=0.047). *In silico* replication of this finding was attempted in a large multi-ethnic systemic JIA case control association study of 982 children with systemic JIA and 8010 healthy controls \[[@r16], [@r17]\]. However, an association between any of the *PDCD1* variants and systemic JIA was not found in the large combined cohort or any of the individual strata that made up the cohort (Table **[3](#T3){ref-type="table"}**).

6.. Discussion
==============

JIA is a complex trait and there is substantial evidence for genetic predisposition to JIA. Many of the variants associated with JIA have also shown to be associated with other autoimmune disorders. While some genes such as *PTPN22* and *STAT4* are associated with multiple autoimmune phenotypes, others such as *NOD2* are associated with specific immune mediated phenotypes such as inflammatory bowel disease. Since variants in *PDCD1* had been associated with SLE, RA and multiple sclerosis, we chose to examine the *PDCD1* gene for an association with JIA as well. To our knowledge, *PDCD1* variants have not been previously investigated for an association with JIA. While the JIA ImmunoChip Consortium identified 17 variants associated with oligoarticular and polyarticular JIA \[[@r5]\], the ImmunoChip array had sparse coverage of variants near the *PDCD1* locus located at the telomeric end of the long arm on chromosome 2, (2q37).

We discovered that *PDCD1* variants showed no association with JIA as a whole, but after stratification by JIA categories, rs11568821 was nominally associated with ERA JIA in our cohort but this association did not withstand permutation procedure. The SNP rs11568821 has been previously shown to be associated with SLE. The other SNP rs7568402, which was associated with systemic JIA in our cohort as it withstood correction by permutation (OR=0.53, p=0.0027), has previously not been associated with other autoimmune phenotypes. However the initial association was not replicated in a large multi-ethnic cohort of systemic JIA patients suggesting our results might reflect a false positive association.

*PDCD1* encodes the inhibitory immunoreceptor PD-1, which belongs to the immunoglobulin superfamily \[[@r18]\]. PD-1 plays an essential role in cell-mediated immunity, and is expressed on T-cells, B-cells and activated monocytes. The programmed death ligand (PD-L) binds to the PD-1 receptor on the cells. The role of the PD-1/PD-L pathway in the prevention of autoimmune diseases has been extensively investigated due to the role of PD-1 in the regulation of autoimmunity and in self-tolerance \[[@r19], [@r20]\]. Activated T-cells express receptors that mediate inhibitory signals from antigen presenting cells. Triggering of receptors on T and B cells and on endothelial and epithelial cells cause release of the two ligands PD-L1 and PD-L2. These ligands inhibit the immune response by binding to the PD-1, therefore preventing the differentiation of self-antigen specific inflammatory T-cells. Thus, variants in *PDCD1* that could potentially alter the function or expression of PD-1, could result in autoimmunity and hence make this an attractive candidate to examine for associations.

Although our JIA cohort is relatively large, individual categories of JIA were still modest in number. While our cases and controls came from different centers, they were all of Northern European ancestry and did not show any evidence of population stratification in other studies that have utilized these cohorts \[[@r5], [@r21]\]. We addressed the issue of multiple comparisons by using a permutation procedure. It should be noted that some of our cases, but not controls were also included in the US stratum of the meta-analysis, but overall the sJIA cohorts did not show any trend towards an association.

A modest association cannot be excluded as our sample size, while considerable was still underpowered for some categories of JIA. Investigations of other cohorts of JIA for genetic association with *PDCD1* variants, as well as meta-analyses would be of interest to definitely exclude PDCD1 as a candidate associated with JIA susceptibility. In summary, *PDCD1* was found not to be associated with JIA as a whole, or with any of the JIA categories.
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###### 

Case-control analyses of PDCD1 variants and juvenile idiopathic arthritis.

               **Cases**   **Controls**                                   
  ------------ ----------- -------------- ----- ------ ------------------ ------
  rs7568402    815         0.43           845   0.44   0.95 (0.82-1.09)   0.45
  rs10204525   830         0.13           855   0.12   1.12 (0.90-1.38)   0.31
  rs11568821   810         0.095          845   0.11   0.84 (0.67-1.05)   0.13
  rs7421861    819         0.33           852   0.33   1.04 (0.90-1.20)   0.63

MAF = minor allele frequency.

OR = odds ratio; 95% CI: 95% confidence interval.

###### 

Case control analysis of PDCD1 variants and JIA categories.

                   **rs7568402**   **rs10204525**         **rs11568821**   **rs7421861**                                                                                               
  ---------------- --------------- ---------------------- ---------------- --------------- ------------------ ------ ----- ----------------------- ----------- ----- ----------------- ------
  Systemic         58              **0.53 (0.35-0.80)**   **0.0027\***     59              1.43 (0.82-2.39)   0.19   55    0.94 (0.48-1.71)        0.85        57    1.44(0.99-2.10)   0.06
  RF-Positive      64              0.88 (0.59-1.28)       0.50             63              1.40 (0.82-2.30)   0.19   62    1.26 (0.70-2.13)        0.42        65    1.12(0.76-1.61)   0.56
  RF-Negative      208             1.05 (0.84-1.31)       0.70             213             1.01 (0.72-1.41)   0.94   204   0.75 (0.51-1.08)        0.14        210   1.09(0.87-1.36)   0.46
  ERA              56              0.83 (0.55-1.23)       0.35             56              1.42 (0.79-2.49)   0.21   55    **0.22 (0.054-0.61)**   **0.012**   55    0.73(0.46-1.12)   0.16
  Oligoarticular   382             1.00 (0.84-1.20)       0.99             389             1.01 (0.77-1.31)   0.96   378   0.96 (0.72-1.26)        0.76        382   1.06(0.89-1.28)   0.50
  Controls         845                                                     855                                       845                                       852                     

OR = odds ratio; 95% CI: 95% confidence interval.

\*p value = 0.047 after 10,000 permutations.

###### 

Minor allele frequencies of *PDCD1* rs7568402 in our cohort compared to a multi-ethnic systemic JIA cohort\*.

  -----------------------------------------------------------------------------------------
  **Population**              **Cases**\   **Controls**\   **Case MAF**   **Control MAF**
                              **n**        **n**                          
  --------------------------- ------------ --------------- -------------- -----------------
  Present study               58           845             0.30           0.44

  **Meta analyses results**                                               

  United States\*             243          1718            0.38           0.44

  United Kingdom              202          4097            0.45           0.43

  Germany                     115          193             0.44           0.46

  Italy                       49           59              0.43           0.41

  Turkey                      49           94              0.35           0.32

  Brazil                      48           62              0.44           0.43

  Argentina                   33           115             0.35           0.35

  Canada                      17           427             0.44           0.40
  -----------------------------------------------------------------------------------------

MAF = minor allele frequency.

\*Some of our cases (but not controls) were included in the US stratum of the meta-analysis.

Meta-analysis p value for SNP rs7568402 is p =0.35.
